Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
November 07, 2023 09:15 ET
|
Capricor Therapeutics
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
October 19, 2023 16:01 ET
|
Capricor Therapeutics
SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
October 10, 2023 09:00 ET
|
Capricor Therapeutics
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s StealthX™ Technology Shows Promise of...
Capricor Therapeutics Announces $23 Million Registered Direct Offering
September 29, 2023 07:35 ET
|
Capricor Therapeutics
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
September 29, 2023 07:30 ET
|
Capricor Therapeutics
-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application (BLA)- -Company On Track to Complete HOPE-3 Enrollment and...
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
September 06, 2023 09:00 ET
|
Capricor Therapeutics
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics...
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 07, 2023 16:05 ET
|
Capricor Therapeutics
-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne...
Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
August 02, 2023 16:01 ET
|
Capricor Therapeutics
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
July 24, 2023 08:30 ET
|
Capricor Therapeutics
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
July 13, 2023 08:30 ET
|
Capricor Therapeutics
-John Hopkins School of Medicine Clinical Director Joins Capricor’s Board of Directors with over 30 Years of Internal Medicine and Infectious Disease Experience- SAN DIEGO, July 13, 2023 (GLOBE...